Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study
Study Overview The study was designed as a phase 2b clinical trial to evaluate the efficacy and safety of rezpegaldesleukin […]
